君实生物双抗ADC获批临床;默沙东K药联合疗法获批新适应症 | 医药早参

每日经济新闻
09 Jan

丨 2025年1月9日星期四丨  NO.1 君实生物注射用JS212临床试验申请获受理  1月8日,君实生物发布公告,称公司收到国家药品监督管理局核准签发的《受理通知书》,注射用JS212(项目代号“JS212”)的临床试验申请获得受理。公告显示,JS212是重组人源化抗表皮生长因子受体(简称“EGFR”)和人表皮生长因子受体3(简称“HER3”)双特异性抗体偶联药物(简称“ADC”),主要用于...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10